Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hyprolose; sodium lauryl sulfate; magnesium stearate; purified talc; titanium dioxide; hypromellose; iron oxide yellow; triacetin - ciavor is indicated for the treatment of: erectile dysfunction (ed) in adult males.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; sodium lauryl sulfate; purified talc; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; triacetin - ciavor is indicated for the treatment of: erectile dysfunction (ed) in adult males; moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: crospovidone; polysorbate 80; magnesium stearate; lactose monohydrate; lactose; povidone; carnauba wax; colour; propylene glycol; indigo carmine; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; industrial methylated spirit; ethanol - evista is indicated for the prevention and treatment of osteoporosis in post-menopausal women. evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified gail model). among the factors included in the modified gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - prasugrel hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - prasugrel hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; triacetin; microcrystalline cellulose; sodium lauryl sulfate; titanium dioxide; hyprolose; iron oxide yellow; iron oxide red; purified talc; magnesium stearate; hypromellose - adcirca is indicated in adults for the treatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine -